Clinical Trials Browser

INDUSTRY × Interventional × Ramucirumab × Clear all

NCT04704934 2026-05-27

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT07098338 2026-05-27

LIBRA

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06445972 2026-05-12

MK-3475-06D

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06448754 2026-05-12

eVOLVE-01

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04145349 2026-05-11

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Phase 1/2 Completed

30 enrolled 16 charts

Sarcoma, Desmoplastic Small Round Cell Tumor

NCT05365581 2026-05-05

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Phase 1 Recruiting

Adenocarcinoma

NCT06996782 2026-05-01

ALTAIR

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03798626 2026-04-01

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Phase 1 Completed

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms

NCT05999994 2026-03-27

CAMPFIRE

Phase 2 Recruiting

Neoplasms

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Solid Cancer

NCT02411448 2026-01-16

RELAY

Phase 3 Active not recruiting

545 enrolled 24 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03281369 2025-12-15

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Phase 1/2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT05980416 2025-11-14

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Phase 1 Terminated

88 enrolled 18 charts

Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms

NCT02597036 2025-10-23

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

Phase 1 Terminated

62 enrolled 25 charts

Other solid neoplasm

Solid Tumors

NCT05071053 2025-08-22

CARMEN-GC01

Phase 2 Terminated

35 enrolled 14 charts

Gastrointestinal

Adenocarcinoma Gastric

NCT05002127 2025-08-07

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Phase 2/3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT02711553 2025-08-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Phase 2 Active not recruiting

309 enrolled 22 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06038578 2025-08-03

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT03013218 2025-08-01

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Phase 1 Completed

Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms

NCT04394624 2025-06-06

CARMEN-LC04

Phase 2 Terminated

31 enrolled 22 charts

Non-small Cell Lung Cancer Metastatic

NCT05311176 2025-05-11

nextHERIZON

Phase 2 Terminated

7 enrolled 8 charts

Gastrointestinal

Stomach Neoplasms

NCT05062980 2025-02-20

Acclaim-2

Phase 1/2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT04499924 2025-01-22

MOUNTAINEER-02

Phase 2/3 Completed

17 enrolled 23 charts

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT02791334 2024-09-27

PACT

Phase 1 Completed

BreastDermatologicGastrointestinal

Breast Neoplasms, Melanoma, Pancreatic Neoplasms

NCT04999761 2024-09-25

AB122 Platform Study

Phase 1 Recruiting

GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT06542731 2024-08-07

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02443324 2024-07-31

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Phase 1 Completed

175 enrolled 23 charts

GastrointestinalGenitourinaryThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT02789345 2024-02-05

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Phase 1 Completed

29 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT06123494 2024-01-16

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Phase 3 Recruiting

Gastrointestinal

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT04151563 2023-12-19

CheckMate 79X

Phase 1/2 Withdrawn

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04145700 2023-09-13

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

Phase 1/2 Terminated

23 enrolled 15 charts

Sarcoma, Sarcoma, Synovial

NCT02426125 2023-08-21

RANGE

Phase 3 Completed

530 enrolled 22 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urethral Neoplasms

NCT05800418 2023-04-05

Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers

Phase 1 Completed

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Stomach Neoplasms

NCT04557384 2023-02-27

A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

Phase 1 Terminated

3 enrolled 9 charts

Other solid neoplasm

Advanced Solid Tumor

NCT02435433 2023-01-20

REACH-2

Phase 3 Completed

399 enrolled 22 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05190445 2022-09-08

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Phase 2 Active not recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT02898077 2022-06-14

A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

Phase 3 Completed

440 enrolled 19 charts

Gastrointestinal

Gastroesophageal Junction Adenocarcinoma

NCT01515306 2022-03-08

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Phase 2 Completed

48 enrolled 17 charts

Other solid neoplasm

Malignant Solid Tumor

NCT02970539 2022-02-16

Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

Phase 1 Unknown

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT00703326 2021-12-06

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Phase 3 Completed

1,144 enrolled 19 charts

Breast Neoplasms

NCT02314117 2021-08-26

RAINFALL

Phase 3 Completed

645 enrolled 22 charts

Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT02564198 2021-08-17

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Phase 1 Completed

29 enrolled 12 charts

Neoplasms, Recurrence, Central Nervous System Neoplasms

NCT02572687 2021-01-20

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Phase 1 Completed

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Neoplasm Metastasis, Stomach Neoplasms

NCT01246986 2021-01-12

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

Phase 2 Completed

204 enrolled 27 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT02082210 2020-12-19

A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

Phase 1/2 Completed

97 enrolled 20 charts

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Liver Neoplasms

NCT02079636 2020-09-11

A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)

Phase 1 Completed

142 enrolled 36 charts

Carcinoma, Non-Small-Cell Lung

NCT02443883 2020-06-29

A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

Phase 2 Completed

164 enrolled 13 charts

Gastrointestinal

Stomach Neoplasms

NCT02514551 2020-06-17

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

Phase 2 Completed

245 enrolled 17 charts

Gastrointestinal

Stomach Neoplasms

NCT02831491 2020-06-09

A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis